We are developing the next generation of targeted immunotherapies using the latest scientific insights, to treat patients affected by cancer and infectious diseases.
EnnoDC I Overview
EnnoDC is a clinical-stage biotech company pioneering the development of first-in-class dendritic cell targeting CD40 receptor specific antigens for immunotherapy in cancer and the prevention of infectious diseases.
We have a growing pipeline of novel immunotherapies, several of which are in clinical development. Target cancers include HPV16+ oropharyngeal and prostate cancer, and infectious diseases, including HIV and COVID.
Our groundbreaking and versatile technology platform harnesses the power of immunotherapy and vaccines by stimulating dendritic cells (DCs) to deliver a more targeted and effective immune response compared to current treatments.
Learn More
EnnoDC I LinKinVax
EnnoDC is the trading
name of LinKinVax.
LinKinVax was founded in 2020 to develop an innovative DC-targeting platform to accelerate the availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI) in France, an institute of INSERM (the French National Institute of Health and Medical Research).
EnnoDC was conceived following an evolution in strategy at LinKinVax to apply the latest scientific insights and the Company’s technology platform to extend its pipeline and develop a new generation of immunotherapies for cancer.
EnnoDC I Team
We are led by a seasoned management team with internationally recognised expertise in medical, industry and business.
Management Team
Supervisory Board
Scientific Advisory Committees
EnnoDC I Partners
EnnoDC is a spin-off of the academic laboratory, the Vaccine Research Institute (VRI) an institute of INSERM (the French National Institute of Health and Medical Research).
The EnnoDC team includes European and US Board members and scientific advisors, and the company has a long-standing collaboration with the Baylor Institute for Immunology Research (Dallas, TX).
EnnoDC is pursuing and developing new collaborations with several internationally regarded cancer institutions including Moffitt Cancer Centre in the US and Gustave Roussy Cancer Campus in France.
EnnoDC is one of the innovative projects selected and supported by the Paris Saclay Cancer Cluster, whose mission is to accelerate the development of innovation in oncology.
EnnoDC I Contact
If you wish to contribute, collaborate or learn more about EnnoDC, we would be delighted to hear from you.
Contact
